The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study

R A W Ploumen*, K B M I Keymeulen, L F S Kooreman, S M J van Kuijk, S Siesling, M L Smidt, T J A van Nijnatten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)60-66
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume48
Issue number1
Early online date22 Oct 2021
DOIs
Publication statusPublished - Jan 2022

Keywords

  • Neoadjuvant systemic therapy
  • Breast cancer
  • Ductal carcinoma in situ
  • PATHOLOGICAL COMPLETE RESPONSE
  • CARCINOMA IN-SITU
  • CHEMOTHERAPY
  • RECOMMENDATIONS
  • METAANALYSIS
  • COMPONENT
  • FUTURE
  • TRIALS

Cite this